Log In
BCIQ
Print this Print this
 

ACTB1011

  Manage Alerts
Collapse Summary General Information
Company ACT Biotech Inc.
DescriptionInhibitor of BCR-ABL tyrosine kinase
Molecular Target BCR-ABL tyrosine kinase (BCR-ABL)
Mechanism of ActionBCR-ABL tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationLeukemia
Indication DetailsTreat Leukemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today